(R) -Lisofylline

(R) -Lisofylline ((R) -Lisophylline) is a (R) -enantiomer of the metabolite of Pentoxifylline with anti-inflammatory properties. (R) -Lisofylline is a lysophosphatidic acid acyltransferase inhibitor with an IC50 of 0.6 μM and interrupts IL-12 signaling-mediated STAT4 activation. (R) -Lisofylline has the potential for type 1 diabetes, autoimmune disorders research[1][2].

Product Specifications

CAS Number

[100324-81-0]

Product Name Alternative

(R) -Lisophylline

UNSPSC

12352005

Target

STAT

Type

Reference compound

Related Pathways

JAK/STAT Signaling; Stem Cell/Wnt

Applications

Metabolism-sugar/lipid metabolism

Field of Research

Metabolic Disease; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/r-lisofylline.html

Purity

99.99

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C(N1CCCC[C@H](O)C)N(C)C2=C(N(C)C=N2)C1=O

Molecular Formula

C13H20N4O3

Molecular Weight

280.32

References & Citations

[1]Elżbieta Wyska, et al. Physiologically Based Modeling of Lisofylline Pharmacokinetics Following Intravenous Administration in Mice. Eur J Drug Metab Pharmacokinet. 2016 Aug;41 (4) :403-12.|[2]B M Hybertson, et al. Lisofylline Prevents Leak, but Not Neutrophil Accumulation, in Lungs of Rats Given IL-1 Intratracheally. J Appl Physiol (1985) . 1997 Jan;82 (1) :226-32.|[3]J J Bright, et al. Prevention of Experimental Allergic Encephalomyelitis via Inhibition of IL-12 Signaling and IL-12-mediated Th1 Differentiation: An Effect of the Novel Anti-Inflammatory Drug Lisofylline. J Immunol. 1998 Dec 15;161 (12) :7015-22.